A top Pfizer executive joined the board of a National Health Service Trust in England, triggering questions about potential conflicts of interest, an NHS-focused news service reported on Wednesday.
Russia's economy has gotten ugly in the past few years, but that has not dampened the enthusiasm of Big Pharma, which continues to like the look of one of the world's largest emerging markets. Pfizer is reportedly the next up with plans for a partnership to produce some of its meds there.
Amgen and Pfizer's Enbrel officially has a biosimilar rival in Europe. And if the rollout goes anything like the recent EU launch of Remicade copy Remsima, the blockbuster brand will be in trouble.
A joint venture between Biogen and South Korean giant Samsung won Europe's first approval for a lower-cost version of Amgen and Pfizer's blockbuster Enbrel, planning to launch its injection in the coming weeks.
Pfizer announced earlier this month that it is financing the drug discovery efforts of four early-stage companies to the tune of a combined $46 million, including 4D Molecular Therapeutics, the maker of a platform for the delivery of gene vectors. In addition, the Big Pharma gained an option to exclusively license at least one adeno-associated virus for cardiac disease targets as a result of the transaction.
Pfizer, breaking into the field of re-engineered T cells for cancer, believes its work with partner Cellectis could eventually top the efforts of more advanced rivals including Novartis.
Pfizer's consumer health unit is said to be destined for sale, but that doesn't mean the business has stopped making its own buys. The drug giant snapped up Treerly Health, the China-based subsidiary of Sirio Pharma, and its portfolio of nutritional products for women, Pfizer said Thursday.
When Pfizer snatched up Hospira last year for $15 billion, the pharma giant said that it didn't have any plans to abandon Hospira's device business once the deal closes. But now Pfizer is having a change of heart, weighing an option to sell Hospira's pump and devices unit as Hospira struggles with its beleaguered business.
Pfizer has been contemplating a large-scale breakup for a while, with analysts expecting the company to split off its established drugs business once it integrates assets from last year's $15 billion Hospira buy. Now, with its Hospira purchase under its belt, the company is thinking about selling off the pumps and devices business it picked up through the deal, potentially laying the foundation for a spinoff.
SAN FRANCISCO-- On Monday, we brought you the lowdown from the J.P. Morgan Healthcare Conference, with company presentations from pharma giants including Novartis and Merck & Co. Today, we're back with our latest roundup, big names and not-so-big.